​MicroTransponder’s Vivistim Paired VNS system is a chest implant that helps chronic ischemic stroke survivors regain impaired motor function in their arms and hands by stimulating the nearby vagus nerve, the body’s “superhighway” of electrical signals. It’s the first product to do so for strokes, earning it the FDA’s breakthrough device designation. Vivistim works to boost the effects of physical therapy, facilitating the development of strength and dexterity at two to three times the degree of recovery without it. “We can implant something, and six weeks later, people are having clinically improved benefits,” MicroTransponder CEO Richard Foust says.

Read More: https://time.com/collection/best-inventions-2023/6324373/microtransponder-vivistim-paired-vns-system/

Radiaction Medical, LTD, an Israel-based medical device company focused on radiation protection for medical staff during interventional procedures, announced that it has appointed industry veteran Christopher Barys to serve as its United States President and Chief Commercial Officer. Barys will lead commercialization efforts and operations in the United States.

Radiaction is a plug-and-play addition to C-arm systems that blocks up to 97% of scatter radiation at the source, offering head-to-toe protection for everyone in the room. Radiaction has received CE Mark approval in Europe and FDA clearance in the United States and is currently being marketed in North America.

Read More: ​https://evtoday.com/news/radiaction-medical-appoints-christopher-barys-as-united-states-president-and-chief-commercial-officer

Luminopia, Inc., a commercial-stage company pioneering a new class of treatments for neuro-visual disorders, today announced that the company’s lead product, Luminopia, was named one of TIME’s Best Inventions of 2023.

Luminopia is the first FDA-approved1 digital therapeutic for a neuro-visual disorder, indicated to improve vision in children, aged 4-7, with amblyopia (lazy eye). Amblyopia is the leading cause of vision loss in children, affecting 3% of children worldwide. Traditional treatments include glasses, eye-patches, and blurring (atropine) eye drops, but these options leave a significant unmet need due to poor compliance, residual vision loss, and negative psychosocial impacts.

Read More: ​https://www.businesswire.com/news/home/20231024543829/en/Luminopia-Named-to-TIME%E2%80%99s-List-of-the-Best-Inventions-of-2023

WHITMORE LAKE, Mich. – Trace Medical has signed a long-term distribution agreement with Outset Medical to rent the Tablo Hemodialysis System to HME providers to meet the growing demand of dialysis patients seeking treatment at home. “We are excited to work with Outset to fill an obvious need in dialysis treatment,” said Greg Apostolou, CEO. “Our chairman was recently diagnosed with renal disease and experienced first-hand the treatment gaps for patients. Together, we see an opportunity for Trace to utilize our national distribution platform and customer base, which serves approximately 30 million patients annually, to address these gaps.” Tablo, cleared by the U.S. Food and Drug Administration, serves as a single enterprise solution that can be used across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by anyone. “Home hemodialysis is the future of dialysis care,” said Steve Williamson, chief commercial officer, Outset Medical. “This new agreement will provide us an additional opportunity to reach the over half million Americans that depend on dialysis to live.” Trace has established a Dialysis Advisory Board with some of the industry’s most prominent nephrologists, GPO leaders and C-suite executives to help educate the industry about the benefits of home hemodialysis and has initiated discussions with commercial payer related to the clinical and financial benefits associated with home hemodialysis.

Read More: https://www.hmenews.com/article/trace-medical-to-distribute-home-dialysis-system

As part of this agreement, Trace Medical will leverage its national distribution network to offer HME providers exclusive access to rent Tablo and meet the growing demand of dialysis patients seeking treatment at home. Greg Apostolou, Chief Executive Officer of Trace Medical, stated, “We are excited to work with Outset to fill an obvious need in dialysis treatment. Our chairman was recently diagnosed with renal disease and experienced first-hand the treatment gaps for patients. Together, we see an opportunity for Trace to utilize our national distribution platform and customer base which serves approximately 30 million patients annually to address these gaps. After months of planning with the talented team at Outset Medical, we are confident in our collective abilities to serve all healthcare channels with Tablo and make a meaningful difference in patient experience and clinical outcomes.”

​Read More: ​https://www.businesswire.com/news/home/20231004237474/en/Trace-Medical-Outset-Medical-sign-long-term-distribution-agreement-for-Tablo%C2%AE-Hemodialysis-System